ArticleCardiovascular diabetology2025
Association of baseline and trajectory of triglyceride-glucose index with the incidence of cardiovascular autonomic neuropathy in type 2 diabetes mellitus.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Two-Time-Point Inflammatory Status Patterns and the Risk of Incident Diabetes: A Cohort Study Based on CHARLS.Healthcare (Basel, Switzerland) · 2026Article
- Blood glucose trajectory phenotypes are associated with in-hospital mortality in a multicenter ICU stroke cohort.Scientific reports · 2026Article
- The association of the combined triglyceride-glucose and frailty index with chronic liver disease: evidence from the CHARLS study.BMC gastroenterology · 2026Article
- Triglyceride-glucose index, genetic susceptibility, and trajectory of microvascular multimorbidity in type 2 diabetes.Scientific reports · 2026Article
- Association of triglyceride glucose index with cardiovascular autonomic neuropathy in type 2 diabetes mellitus.Frontiers in cardiovascular medicine · 2026Article
- Association between triglyceride-glucose-related indices and liver-related events in patients with type 2 diabetes.Frontiers in endocrinology · 2026Article
- The association between triglyceride-glucose index and all-cause/cardiovascular mortality in patients with different glucose metabolism statuses.Cardiovascular diabetology · 2025Article
- The triglyceride-glucose index: updating evidence from clinical settings to molecular mechanisms in ageing-related cerebrovascular diseases.Cardiovascular diabetology · 2025Review
- Association of hepatic biomarkers with incident diabetes: a mediation analysis of the triglyceride-glucose index in a large Chinese cohort.Lipids in health and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCardiovascular autonomic neuropathy (CAN), characterized by disrupted autonomic regulation of the cardiovascular system, is a frequent complication associated with diabetes. The triglyceride-glucose (TyG) index represents a precise insulin resistance indicator. However, the influence of baseline and prolonged TyG index patterns on CAN risk in type 2 diabetes remains unclear.
methodsBased on the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, multivariate logistic regression models and restricted cubic splines (RCS) were deployed for elucidating the relation between baseline TyG index and the incidence of CAN. The area under the curve (AUC) of receiver operating characteristic (ROC) curve was used to assess the diagnostic value of the TyG index in predicting the risk of CAN. The relationship between TyG trajectory and the occurrence of CAN in individuals with diabetes was examined using Kaplan-Meier curve and a multivariable Cox proportional hazards regression model. Subgroup analysis was used to assess the robustness of the results. Additionally, we explored the impact of intensive glycemia treatment on the relationship between trajectory of TyG index and CAN risk.
resultsIn this study, these in the top quartile of the TyG index had a greater likelihood of developing CAN (TyG index Q4 vs. Q1 in Model II, OR = 1.29, 95% CI 1.03-1.62, P = 0.027). RCS indicated a rising trend in the TyG index in relation to the incidence of CAN. The AUC of the TyG index for predicting the occurrence of CAN was 0.636 (95% CI 0.620-0.651; P < 0.001), with the cut-off value of 0.208. During a 7-year follow-up period, three unique TyG trajectories were recognized: class 1 (n = 431, 23.26%), class 2 (n = 798, 27.57%), and class 3 (n = 293, 31.71%). Notable discrepancies in CAN risk across various trajectories were identified in Kaplan-Meier curve (P < 0.001). Cox regression analysis indicated that individuals in class 3 experienced a greater incidence of CAN in comparison to those in class 1 after adjusting for all covariates. Subgroup analysis found no significant effect modification in this relationship. Additionally, in the intensive glycemia group, class 2 had a reduced risk of CAN, while class 3 had an increased risk when compared to standard glycemia group.
conclusionIncreased baseline levels and long-term trajectory of TyG index are associated with an increased incidence of CAN. Intensive glycemic therapy might influence the association between the trajectory of TyG index and the chance of developing CAN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.